Stockholders' Equity (Details)													1 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 16, 2024 USD ($) $ / shares shares	Sep. 12, 2024 $ / shares shares	Sep. 05, 2024 USD ($) $ / shares shares	Apr. 08, 2024 USD ($) shares	Feb. 20, 2024 USD ($) $ / shares shares	Nov. 30, 2023 USD ($) $ / shares shares	Jul. 24, 2023 USD ($)	Jul. 16, 2023 $ / shares	May 04, 2023 USD ($)	Apr. 30, 2022 USD ($) $ / shares shares	Feb. 02, 2022 shares	Jan. 10, 2022 shares	Jun. 30, 2023 $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	May 06, 2024 $ / shares	Dec. 31, 2023 $ / shares shares	Aug. 31, 2021 shares	Jul. 31, 2021 shares	Feb. 18, 2014 $ / shares shares
Stockholders’ Equity [Line Items]
Common stock shares authorized (in Shares) | shares														130,000,000		130,000,000			130,000,000			130,000,000
Preferred stock shares authorized (in Shares) | shares																						20,000,000
Par value (in Dollars per share)																						$ 0.001
Issuance of common stock (in Shares) | shares		55,000		10,436
Price of per share (in Dollars per share)		$ 0.001
Warrant exercise price decrease (in Dollars per share)	$ 0.125
Warrant term		5 years
Exercise price (in Dollars per share)	$ 3.55
Purchase of warrant shares (in Shares) | shares													250,000
Gross proceeds (in Dollars) | $																$ 4,306,000
Cash received (in Dollars) | $														$ 992		992
Gross proceeds from sale of common stock (in Dollars) | $									$ 5,500,000							$ 2,106,000	$ 453,000
Percentage of gross proceeds									3.00%
Sale of stock price (in Dollars per share)																		$ 1
Conversion rate description																(i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $25.00 per share
Purchase exceed amount (in Dollars) | $																$ 500,000,000
Purchase of shares (in Shares) | shares																100,000
Percentage of outstanding shares																4.99%
Expiration date													5 years
Fair value of warrant grant date (in Dollars per share)													$ 3,164
Fair value of per warrant grant date (in Dollars per share)													12.64
Fair value price (in Dollars per share)													$ 24
Daily return rate													5.18%
Short-term annual volatility													100.00%
Standard deviation													6.30%
Expected term	3 years
Pre-Funded Warrants [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock (in Shares) | shares		1,167,850
Warrant exercise price decrease (in Dollars per share)		$ 0.0001
Common Warrants [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock (in Shares) | shares		1,222,850
Price of per share (in Dollars per share)		$ 3.55
Warrant exercise price increase (in Dollars per share)		3.68
Common Warrant [Member]
Stockholders’ Equity [Line Items]
Price of per share (in Dollars per share)		$ 3.68
Series A New Warrants [Member]
Stockholders’ Equity [Line Items]
Warrant term	5 years
Exercise price (in Dollars per share)	$ 4.28
Purchase of warrant shares (in Shares) | shares	1,222,850
Weighted-average grant-date fair value of options granted (in Dollars per share)	$ 5.49
Exercisable term	3 years
Series B New Warrants [Member]
Stockholders’ Equity [Line Items]
Warrant term	3 years
Exercise price (in Dollars per share)	$ 4.28
Purchase of warrant shares (in Shares) | shares	1,222,850
Weighted-average grant-date fair value of options granted (in Dollars per share)	$ 4.87
Warrant [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)										$ 400
Gross proceeds (in Dollars) | $	$ 4,300,000
Issued offering warrants (in Shares) | shares						5,625
Common stock exercise price (in Dollars per share)						$ 15.52
Weighted-average grant-date fair value of options granted (in Dollars per share)						$ 10.32				$ 220
Expiration date						5 years
Fair value of warrant grant date (in Dollars per share)								$ 25.168
Series B Warrants [Member]
Stockholders’ Equity [Line Items]
Weighted-average grant-date fair value of options granted (in Dollars per share)			$ 2.25
Fair value of warrant			5
Issuance cost (in Dollars) | $			$ 37
Expiration date			5 years
Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Weighted-average grant-date fair value of options granted (in Dollars per share)					$ 4.88
Purchase Agreement [Member] | Series A New Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)	$ 4.28
Issued offering warrants (in Shares) | shares	1,222,850
Purchase Agreement [Member] | Series B New Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)	$ 4.28
Issued offering warrants (in Shares) | shares	1,222,850													16,214		16,214
Purchase Agreement [Member] | Series A Preferred Stock and Warrants [Member]
Stockholders’ Equity [Line Items]
Issued offering warrants (in Shares) | shares														258,374		258,374
Purchase Agreement [Member] | Series A Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)					$ 4.28
Issued offering warrants (in Shares) | shares					51,937
Purchase Agreement [Member] | Series B Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)			$ 4.28
Issued offering warrants (in Shares) | shares			16,214
Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock sold (in Shares) | shares														37,618		48,849
Weighted average price (in Dollars per share)														$ 4.56		$ 5.56
Net proceeds (in Dollars) | $														$ 164		$ 260,000
Common Stock [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Warrant term														5 years		5 years
Aggregate offering price (in Dollars) | $					$ 2,437											$ 550,000
Common stock exercise price (in Dollars per share)																$ 4.2756
Additional Paid-in Capital [Member] | Warrant [Member]
Stockholders’ Equity [Line Items]
Issuance cost (in Dollars) | $						$ 58,000				$ 264
Expected term [Member]
Stockholders’ Equity [Line Items]
Fair value of warrants														5		5
Fair value of warrant						5				5			4.9
Expected term [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Fair value of warrant					5
Expected volatility [Member]
Stockholders’ Equity [Line Items]
Fair value of warrants														68.4		68.4
Dividend yield [Member]
Stockholders’ Equity [Line Items]
Fair value of warrants														0		0
Fair value of warrant										0
Dividend yield			0.00%			0.00%
Dividend yield [Member] | Series A New Warrants [Member]
Stockholders’ Equity [Line Items]
Dividend yield	0.00%
Dividend yield [Member] | Series B New Warrants [Member]
Stockholders’ Equity [Line Items]
Dividend yield	0.00%
Dividend yield [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Dividend yield					0.00%
Risk-free interest rate [Member]
Stockholders’ Equity [Line Items]
Fair value of warrants														3.4		3.4
Fair value of warrant										2.92			3.99
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			3.50%			4.41%
Risk-free interest rate [Member] | Series A New Warrants [Member]
Stockholders’ Equity [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	3.40%
Risk-free interest rate [Member] | Series B New Warrants [Member]
Stockholders’ Equity [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	3.40%
Risk-free interest rate [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					4.30%
Measurement Input, Option Volatility [Member]
Stockholders’ Equity [Line Items]
Fair value of warrant										62.55			60
Expected volatility			68.40%			68.89%
Measurement Input, Option Volatility [Member] | Series A New Warrants [Member]
Stockholders’ Equity [Line Items]
Expected volatility	68.40%
Expected term	5 years
Measurement Input, Option Volatility [Member] | Series B New Warrants [Member]
Stockholders’ Equity [Line Items]
Expected volatility	68.40%
Measurement Input, Option Volatility [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Expected volatility					68.24%
Restricted Stock Units (RSUs) [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock (in Shares) | shares				11,387
Options were cancelled (in Shares) | shares				5,226
Fair value vested issuance (in Dollars) | $				$ 32,000
Underwriting Agreement [Member]
Stockholders’ Equity [Line Items]
Purchase of warrant shares (in Shares) | shares										1,200
IPO [Member] | Purchase Agreement [Member] | Warrant [Member]
Stockholders’ Equity [Line Items]
Issuance cost (in Dollars) | $					$ 254
Convertible Note Payable [Member]
Stockholders’ Equity [Line Items]
Warrant term														5 years		5 years
Exercise price (in Dollars per share)					$ 10.164	$ 15.52
Issued offering warrants (in Shares) | shares					157,094
Conversion shares (in Shares) | shares					84,729
At-the-Market Offering Program [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock sold (in Shares) | shares																129,199
Sale of stock price (in Dollars per share)														$ 14.63		$ 14.63
Net of issuance costs (in Dollars) | $																$ 1,834
2012 Plan [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Number of shares of common stock reserved for issuance (in Shares) | shares														662,516		662,516					737,516
2012 Plan [Member] | Minimum [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Number of shares of common stock reserved for issuance (in Shares) | shares																				737,516
2012 Plan [Member] | Maximum [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Number of shares of common stock reserved for issuance (in Shares) | shares																				799,266
2022 Plan [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock (in Shares) | shares															144,196
Percentage of gross proceeds											4.00%
Common stock sold (in Shares) | shares											1,100,000	1,100,000
Percentage of outstanding shares												4.00%
2022 Plan [Member] | Common Stock [Member]
Stockholders’ Equity [Line Items]
Common stock sold (in Shares) | shares											1,600,000	1,600,000
Equity Line of Credit [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock (in Shares) | shares																10,000
Lincoln Park Capital Fund, LLC [Member]
Stockholders’ Equity [Line Items]
Price of per share (in Dollars per share)														$ 1.5		$ 1.5
Net of issuance costs (in Dollars) | $							$ 10,000,000
Line of credit (in Dollars) | $																$ 10,000,000
Series A Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Preferred stock shares authorized (in Shares) | shares														4,500,000		4,500,000			4,500,000			4,500,000
Par value (in Dollars per share)														$ 0.001		$ 0.001			$ 0.001
Description of series A preferred stock																the product of (x) $15.125 multiplied by (y) the sum of 1 plus the product of (A) 0.06 multiplied by (B) a fraction equal to the number of days that such share of Series A Preferred Stock has been issued divided by 365. “Conversion Price” means (i) for the shares of Series A Preferred Stock issued on the Closing Date, $1.5125 and (ii) for each share of Series A Preferred Stock issued thereafter, an amount equal to the greater of (x) $1.5125 and the average of the VWAPs for the 10 Trading Days prior the issuance date of such share of Series A Preferred Stock, in each case subject to adjustment as set forth herein. On any date that ten out of the last 15 daily VWAPs of the Common Stock is 250% higher than the Conversion Price on such date, then the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock. Additionally, on and after the time on which the Company has $2.25 million in revenues in any single financial quarter, the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock (a “Required Conversion”). No dividends are payable on the Series A Preferred Stock. The Series A Preferred Stock will vote together with the Common Stock on all matters other than as required by law; provided however that any additional shares underlying the Series A Preferred Stock as a result of the anti-dilution provision described below shall not vote on an “as converted” basis and shall only vote when issued upon conversion. Notwithstanding the foregoing, the vote of an individual holder of Series A Preferred Stock (and underlying Common Stock) shall be capped at 9.99% (or 4.99% if selected by the holder).
Percentage of shares issued to stockholders																50.00%
Deemed liquidation percentage																110.00%
Increased percentage of deemed liquidation																10.00%
Transaction excess amount (in Dollars) | $																$ 1,000,000
Series A Preferred Stock [Member] | Common Stock [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)					$ 1.2705
Series A Preferred Stock [Member] | Merger Transaction [Member]
Stockholders’ Equity [Line Items]
Equity percentage														50.00%		50.00%
Series A Preferred Stock [Member] | Convertible Note Payable [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Exercise price (in Dollars per share)					$ 1.2705
Series B Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Preferred stock shares authorized (in Shares) | shares														491,222		491,222			491,222			491,222
Par value (in Dollars per share)														$ 0.001		$ 0.001			$ 0.001
Percentage of shares issued to stockholders																50.00%
Deemed liquidation percentage																110.00%
Increased percentage of deemed liquidation																10.00%
Description of series B preferred stock																the product of (x) $6.3625 multiplied by (y) the sum of 1 plus the product of (A) 0.06 multiplied by (B) a fraction equal to the number of days that such share of Series B Preferred Stock has been issued divided by 365. “Conversion Price” means $5.09 per share, subject to adjustment as set forth herein. On any date that ten out the last 15 daily VWAPs of the Common Stock is 250% higher than the Conversion Price on such date, then the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock. Additionally, on and after the time on which the Company has $2.25 million in revenues in any single financial quarter, the Company will have the right to require 50% of the Preferred Stock to be converted into shares of Common Stock (a “Required Conversion”). No dividends are payable on the Series B Preferred Stock. The Series B Preferred Stock will vote together with the Common Stock on all matters other than as required by law; provided however that any additional shares underlying the Series B Preferred Stock as a result of the anti-dilution provision described below shall not vote on an “as converted” basis and shall only vote when issued upon conversion. Notwithstanding the foregoing, the vote of an individual holder of Series B Preferred Stock (and underlying Common Stock) shall be capped at 9.99% (or 4.99% if selected by the holder).
Indebtedness single transaction (in Dollars) | $																$ 1,000,000
Series B Preferred Stock [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock (in Shares) | shares																86,454
Series B Preferred Stock [Member] | Merger Transaction [Member]
Stockholders’ Equity [Line Items]
Equity percentage														50.00%		50.00%
Series A Preferred Stock and Warrants [Member] | Purchase Agreement [Member]
Stockholders’ Equity [Line Items]
Issuance of common stock (in Shares) | shares																172,239
Common Stock [Member] | Series A New Warrants [Member]
Stockholders’ Equity [Line Items]
Warrant term	5 years